Form 4: Avalo Therapeutics Director Michael Heffernan Granted Stock Options

Director Michael Heffernan received stock options for 50,000 shares of Avalo Therapeutics, Inc. (AVTX) on March 25, 2025.

Summary

• Michael Thomas Heffernan, a director of Avalo Therapeutics, Inc. (AVTX), was granted stock options on March 25, 2025.
• The options give him the right to buy 50,000 shares of AVTX common stock at an exercise price of $8.54 per share.
• The options vest in three equal annual installments, starting on the first anniversary of the grant date, contingent upon continued service as a director.
• The options expire on March 25, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns the director's interests with those of the shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice for compensating and incentivizing directors and executives in publicly traded companies, particularly in the biotechnology sector.

Comparison to Industry Standards

• Stock option grants for directors in similar-sized biotech companies typically range from a few thousand to tens of thousands of shares, depending on the company's stage of development and the director's role.
• The vesting schedule of three years is a standard practice to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to increase shareholder value.
• The director benefits from the potential to profit from the increase in the company's stock price.

Key Dates

Keywords

stock options, director, Avalo Therapeutics, AVTX, Michael Heffernan, equity, grant